{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:15:13Z","timestamp":1788786913330,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007194","name":"Wenzhou Municipal Science and Technology Bureau","doi-asserted-by":"crossref","award":["Y20220860, Y20220894"],"award-info":[{"award-number":["Y20220860, Y20220894"]}],"id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32470969"],"award-info":[{"award-number":["32470969"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"crossref","award":["2021C03120"],"award-info":[{"award-number":["2021C03120"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-025-01134-w","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:40:35Z","timestamp":1768311635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["IRF1 suppresses gastric tumorigenesis via dual PI3K\/AKT-ERK pathway modulation and functional antagonism of oncogenic MX2"],"prefix":"10.1007","volume":"49","author":[{"given":"Wenjing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neng","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xietao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"1134_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","volume":"286\u2013287","author":"D Sonkin","year":"2024","unstructured":"D. Sonkin, A. Thomas, B.A. Teicher, cancer treatments: past, present, and future. Cancer Genet. 286\u2013287, 18\u201324 (2024)","journal-title":"Cancer Genet."},{"issue":"3","key":"1134_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"F. Bray, M. Laversanne, H. Sung, J. Ferlay, R.L. Siegel, I. Soerjomataram et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74(3), 229\u2013263 (2024)","journal-title":"CA Cancer J. Clin."},{"issue":"10125","key":"1134_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"C. Allemani, T. Matsuda, Di V. Carlo, R. Harewood, M. Matz, M. Niksic et al., Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 391(10125), 1023\u20131075 (2018)","journal-title":"Lancet"},{"issue":"11","key":"1134_CR4","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","volume":"20","author":"M Arnold","year":"2019","unstructured":"M. Arnold, M.J. Rutherford, A. Bardot, J. Ferlay, T.M. Andersson, T.A. Myklebust et al., Progress in cancer survival, mortality, and incidence in seven high-income countries 1995\u20132014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 20(11), 1493\u20131505 (2019)","journal-title":"Lancet Oncol."},{"issue":"3","key":"1134_CR5","first-page":"264","volume":"71","author":"SS Joshi","year":"2021","unstructured":"S.S. Joshi, B.D. Badgwell, Current treatment and recent progress in gastric cancer. CA Cancer J. Clin. 71(3), 264\u2013279 (2021)","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"1134_CR6","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"C.S. Fuchs, T. Doi, R.W. Jang, K. Muro, T. Satoh, M. Machado et al., Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 4(5), e180013 (2018)","journal-title":"JAMA Oncol."},{"key":"1134_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","volume":"202","author":"S Pestka","year":"2004","unstructured":"S. Pestka, C.D. Krause, M.R. Walter, Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8\u201332 (2004)","journal-title":"Immunol. Rev."},{"key":"1134_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev-pathol-031920-093932","volume":"16","author":"GM Boukhaled","year":"2021","unstructured":"G.M. Boukhaled, S. Harding, D.G. Brooks, Opposing roles of type I interferons in cancer immunity. Annu. Rev. Pathol. 16, 167\u2013198 (2021)","journal-title":"Annu. Rev. Pathol."},{"issue":"4","key":"1134_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","volume":"50","author":"HM Lazear","year":"2019","unstructured":"H.M. Lazear, J.W. Schoggins, M.S. Diamond, Shared and distinct functions of type I and type III interferons. Immunity. 50(4), 907\u2013923 (2019)","journal-title":"Immunity"},{"issue":"3","key":"1134_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tcb.2022.06.010","volume":"33","author":"EN Chin","year":"2023","unstructured":"E.N. Chin, A. Sulpizio, L.L. Lairson, Targeting STING to promote antitumor immunity. Trends Cell. Biol. 33(3), 189\u2013203 (2023)","journal-title":"Trends Cell. Biol."},{"issue":"5164","key":"1134_CR11","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1126\/science.8197455","volume":"264","author":"JE Darnell Jr","year":"1994","unstructured":"J.E. Jr. Darnell, I.M. Kerr, G.R. Stark, Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264(5164), 1415\u20131421 (1994)","journal-title":"Science"},{"issue":"7","key":"1134_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"L. Zitvogel, L. Galluzzi, O. Kepp, M.J. Smyth, G. Kroemer, Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15(7), 405\u2013414 (2015)","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"1134_CR13","first-page":"549","volume":"12","author":"P Xu","year":"2022","unstructured":"P. Xu, X. Chen, Y. Xu, L. Fu, Y. Li, H. Fu et al., Trastuzumab in combination with pegylated interferon-alpha1b exerts synergistic antitumor activity through enhanced Inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity. Am. J. Cancer Res. 12(2), 549\u2013561 (2022)","journal-title":"Am. J. Cancer Res."},{"issue":"2","key":"1134_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<290::AID-CNCR4>3.0.CO;2-P","volume":"85","author":"GR Hudes","year":"1999","unstructured":"G.R. Hudes, S. Lipsitz, J. Grem, M. Morrisey, L. Weiner, J.W. Kugler et al., A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern cooperative oncology group study (E5292). Cancer. 85(2), 290\u2013294 (1999)","journal-title":"Cancer"},{"issue":"4","key":"1134_CR15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/bjc.1994.382","volume":"70","author":"MT Seymour","year":"1994","unstructured":"M.T. Seymour, P.W. Johnson, M.R. Hall, P.F. Wrigley, M.L. Slevin, Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study. Br. J. Cancer. 70(4), 719\u2013723 (1994)","journal-title":"Br. J. Cancer"},{"issue":"7344","key":"1134_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"J.W. Schoggins, S.J. Wilson, M. Panis, M.Y. Murphy, C.T. Jones, P. Bieniasz et al., A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 472(7344), 481\u2013485 (2011)","journal-title":"Nature"},{"key":"1134_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1146\/annurev.immunol.19.1.623","volume":"19","author":"T Taniguchi","year":"2001","unstructured":"T. Taniguchi, K. Ogasawara, A. Takaoka, N. Tanaka, IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19, 623\u2013655 (2001)","journal-title":"Annu. Rev. Immunol."},{"key":"1134_CR18","doi-asserted-by":"crossref","unstructured":"R. Karki, B.R. Sharma, E. Lee, B. Banoth, R.K.S. Malireddi, P. Samir et al., Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer. JCI Insight. 5(12) (2020)","DOI":"10.1172\/jci.insight.136720"},{"key":"1134_CR19","doi-asserted-by":"crossref","unstructured":"G. Ghislat, A.S. Cheema, E. Baudoin, C. Verthuy, P.J. Ballester, K. Crozat et al., NF-kappaB-dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity. Sci. Immunol. 6(61) (2021)","DOI":"10.1126\/sciimmunol.abg3570"},{"issue":"24","key":"1134_CR20","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1158\/0008-5472.CAN-21-2078","volume":"81","author":"S Yokoyama","year":"2021","unstructured":"S. Yokoyama, A. Takahashi, R. Kikuchi, S. Nishibu, J.A. Lo, M. Hejna et al., SOX10 regulates melanoma immunogenicity through an IRF4-IRF1 axis. Cancer Res. 81(24), 6131\u20136141 (2021)","journal-title":"Cancer Res."},{"issue":"1","key":"1134_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/ni1538","volume":"9","author":"S Kano","year":"2008","unstructured":"S. Kano, K. Sato, Y. Morishita, S. Vollstedt, S. Kim, K. Bishop et al., The contribution of transcription factor IRF1 to the interferon-gamma-interleukin 12 signaling axis and TH1 versus TH-17 differentiation of CD4\u2009+\u2009T cells. Nat. Immunol. 9(1), 34\u201341 (2008)","journal-title":"Nat. Immunol."},{"issue":"9","key":"1134_CR22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nri1900","volume":"6","author":"K Honda","year":"2006","unstructured":"K. Honda, T. Taniguchi, IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6(9), 644\u2013658 (2006)","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"1134_CR23","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1016\/j.immuni.2022.10.020","volume":"55","author":"S Lukhele","year":"2022","unstructured":"S. Lukhele, D.A. Rabbo, M. Guo, J. Shen, H.J. Elsaesser, R. Quevedo et al., The transcription factor IRF2 drives interferon-mediated CD8(+) T cell exhaustion to restrict anti-tumor immunity. Immunity. 55(12), 2369\u201385e10 (2022)","journal-title":"Immunity"},{"issue":"8","key":"1134_CR24","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/2326-6066.CIR-18-0711","volume":"7","author":"L Shao","year":"2019","unstructured":"L. Shao, W. Hou, N.E. Scharping, F.P. Vendetti, R. Srivastava, C.N. Roy et al., IRF1 inhibits antitumor immunity through the upregulation of PD-L1 in the tumor cell. Cancer Immunol. Res. 7(8), 1258\u20131266 (2019)","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"1134_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.canlet.2015.01.003","volume":"359","author":"L Yuan","year":"2015","unstructured":"L. Yuan, C. Zhou, Y. Lu, M. Hong, Z. Zhang, Z. Zhang et al., IFN-gamma-mediated IRF1\/miR-29b feedback loop suppresses colorectal cancer cell growth and metastasis by repressing IGF1. Cancer Lett. 359(1), 136\u2013147 (2015)","journal-title":"Cancer Lett."},{"issue":"1","key":"1134_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13046-019-1186-z","volume":"38","author":"L Jiang","year":"2019","unstructured":"L. Jiang, J.Y. Liu, Y. Shi, B. Tang, T. He, J.J. Liu et al., MTMR2 promotes invasion and metastasis of gastric cancer via inactivating IFNgamma\/STAT1 signaling. J. Exp. Clin. Cancer Res. 38(1), 206 (2019)","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1134_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.canlet.2019.05.006","volume":"457","author":"J Yuan","year":"2019","unstructured":"J. Yuan, Z. Yin, L. Tan, W. Zhu, K. Tao, G. Wang et al., Interferon regulatory factor-1 reverses chemoresistance by downregulating the expression of P-glycoprotein in gastric cancer. Cancer Lett. 457, 28\u201339 (2019)","journal-title":"Cancer Lett."},{"issue":"4","key":"1134_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"JA Ajani","year":"2023","unstructured":"J.A. Ajani, T.A. D\u2019Amico, D.J. Bentrem, D. Cooke, C. Corvera, P. Das et al., Esophageal and esophagogastric junction Cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 21(4), 393\u2013422 (2023)","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"10251","key":"1134_CR29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"E.C. Smyth, M. Nilsson, H.I. Grabsch, van N.C. Grieken, F. Lordick, Gastric cancer. Lancet. 396(10251), 635\u2013648 (2020)","journal-title":"Lancet"},{"issue":"1","key":"1134_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"W.L. Guan, Y. He, R.H. Xu, Gastric cancer treatment: recent progress and future perspectives. J. Hematol. Oncol. 16(1), 57 (2023)","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"1134_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41418-022-01097-7","volume":"30","author":"K Gao","year":"2023","unstructured":"K. Gao, Q. Shi, Y. Gu, W. Yang, Y. He, Z. Lv et al., SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis. Cell. Death Differ. 30(2), 475\u2013487 (2023)","journal-title":"Cell. Death Differ."},{"key":"1134_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.canlet.2021.03.002","volume":"506","author":"Y Yan","year":"2021","unstructured":"Y. Yan, L. Zheng, Q. Du, H. Yazdani, K. Dong, Y. Guo et al., Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10\/CXCR3 axis in hepatocellular carcinoma (HCC). Cancer Lett. 506, 95\u2013106 (2021)","journal-title":"Cancer Lett."},{"issue":"6","key":"1134_CR33","doi-asserted-by":"publisher","first-page":"114289","DOI":"10.1016\/j.celrep.2024.114289","volume":"43","author":"PK Purbey","year":"2024","unstructured":"P.K. Purbey, J. Seo, M.K. Paul, K.S. Iwamoto, A.E. Daly, A.C. Feng et al., Opposing tumor-cell-intrinsic and -extrinsic roles of the IRF1 transcription factor in antitumor immunity. Cell. Rep. 43(6), 114289 (2024)","journal-title":"Cell. Rep."},{"issue":"3","key":"1134_CR34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41419-024-06566-0","volume":"15","author":"L Ge","year":"2024","unstructured":"L. Ge, Y. Rui, C. Wang, Y. Wu, H. Wang, J. Wang, The RNA m(6)A reader IGF2BP3 regulates NFAT1\/IRF1 axis-mediated anti-tumor activity in gastric cancer. Cell. Death Dis. 15(3), 192 (2024)","journal-title":"Cell. Death Dis."},{"key":"1134_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cancergen.2024.09.002","volume":"288\u2013289","author":"Y Wang","year":"2024","unstructured":"Y. Wang, J. Wang, T. Zeng, J. Qi, Data-mining-based biomarker evaluation and experimental validation of SHTN1 for bladder cancer. Cancer Genet. 288\u2013289, 43\u201353 (2024)","journal-title":"Cancer Genet."},{"issue":"1","key":"1134_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.7150\/jca.100922","volume":"16","author":"H Liu","year":"2025","unstructured":"H. Liu, Y. Li, M. Karsidag, T. Tu, P. Wang, Technical and biological biases in bulk transcriptomic data mining for cancer research. J. Cancer. 16(1), 34\u201343 (2025)","journal-title":"J. Cancer"},{"issue":"2","key":"1134_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.21147\/j.issn.1000-9604.2025.02.12","volume":"37","author":"H Liu","year":"2025","unstructured":"H. Liu, J.P. Dilger, Different strategies for cancer treatment: targeting cancer cells or their neighbors? Chin. J. Cancer Res. 37(2), 289\u2013292 (2025)","journal-title":"Chin. J. Cancer Res."},{"issue":"1","key":"1134_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40364-024-00620-x","volume":"12","author":"H Liu","year":"2024","unstructured":"H. Liu, J. Weng, C.L. Huang, A.P. Jackson, Voltage-gated sodium channels in cancers. Biomark. Res. 12(1), 70 (2024)","journal-title":"Biomark. Res."},{"issue":"5","key":"1134_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s10142-024-01443-7","volume":"24","author":"H Liu","year":"2024","unstructured":"H. Liu, J. Weng, C.L. Huang, A.P. Jackson, Is the voltage-gated sodium channel beta3 subunit (SCN3B) a biomarker for glioma? Funct. Integr. Genomics. 24(5), 162 (2024)","journal-title":"Funct. Integr. Genomics"},{"issue":"6","key":"1134_CR40","doi-asserted-by":"publisher","first-page":"167844","DOI":"10.1016\/j.bbadis.2025.167844","volume":"1871","author":"H Liu","year":"2025","unstructured":"H. Liu, S.W. Hamaia, L. Dobson, J. Weng, F.L. Hernandez, C.A. Beaudoin et al., The voltage-gated sodium channel beta3 subunit modulates C6 glioma cell motility independently of channel activity. Biochim. Biophys. Acta Mol. Basis Dis. 1871(6), 167844 (2025)","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"5","key":"1134_CR41","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.chom.2014.09.021","volume":"16","author":"JL Fribourgh","year":"2014","unstructured":"J.L. Fribourgh, H.C. Nguyen, K.A. Matreyek, F.J.D. Alvarez, B.J. Summers, T.G. Dewdney et al., Structural insight into HIV-1 restriction by MxB. Cell. Host Microbe. 16(5), 627\u2013638 (2014)","journal-title":"Cell. Host Microbe"},{"issue":"10","key":"1134_CR42","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.chom.2024.09.002","volume":"32","author":"GD Moschonas","year":"2024","unstructured":"G.D. Moschonas, L. Delhaye, R. Cooreman, F. Husers, A. Bhat, Z. Stylianidou et al., MX2 forms nucleoporin-comprising cytoplasmic biomolecular condensates that lure viral capsids. Cell. Host Microbe. 32(10), 1705\u201324e14 (2024)","journal-title":"Cell. Host Microbe"},{"issue":"11","key":"1134_CR43","doi-asserted-by":"publisher","first-page":"18762","DOI":"10.1002\/jcb.29189","volume":"120","author":"H Wang","year":"2019","unstructured":"H. Wang, Q. Guan, Y. Nan, Q. Ma, Y. Zhong, Overexpression of human MX2 gene suppresses cell proliferation, migration, and invasion via ERK\/P38\/NF-kappaB pathway in glioblastoma cells. J. Cell. Biochem. 120(11), 18762\u201318770 (2019)","journal-title":"J. Cell. Biochem."},{"issue":"8","key":"1134_CR44","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1002\/cam4.3846","volume":"10","author":"M Juraleviciute","year":"2021","unstructured":"M. Juraleviciute, J. Nsengimana, J. Newton-Bishop, G.J. Hendriks, A. Slipicevic, MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy. Cancer Med. 10(8), 2840\u20132854 (2021)","journal-title":"Cancer Med."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-025-01134-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-025-01134-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-025-01134-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T02:02:52Z","timestamp":1768356172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-025-01134-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1134"],"URL":"https:\/\/doi.org\/10.1007\/s13402-025-01134-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6435174\/v1","asserted-by":"object"}]},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of The First Affiliated Hospital, Wenzhou medical University (Ethical Approval 2021-R092). Animal care and experiments were conducted following the guidelines of the Department of Laboratory Animals of Wenzhou Medical University. Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to publish this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}